4
Orphan Designations
0 approved, 4 designated
0
FDA Approvals
1
Active Trials
200 recruiting
7
Rare Diseases
across 11 areas
0
News (30d)
Quiet
Recursion Pharmaceuticals Inc. is a company with 4 orphan drug designations across 7 rare diseases. Active clinical trials in 1 indication.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| cerebral cavernous malformation | 4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl | Des.TrialAppr. |
| classic familial adenomatous polyposis | 3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-[(2-fluoro-4-iodophenyl)amino]-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione | Des.TrialAppr. |
| lymphoma | - | Des.TrialAppr. |
| meningioma | N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide | Des.TrialAppr. |
| neurilemmoma of the pleura | N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide | Des.TrialAppr. |
| schwannoma of twelfth cranial nerve | N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide | Des.TrialAppr. |
| schwannoma of ureter | N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/7
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/7
candidate diseases
0
avg importance: 0
0
affecting portfolio